mouse anti ifit3  (Proteintech)

Journal: Frontiers in Immunology

Article Title: IFIT3 activation significantly contributes to HIV-1-associated neurodegenerative disorder-mediated neuroinflammation

doi: 10.3389/fimmu.2025.1532318

Figure Lengend Snippet: Effects of antiretroviral drugs on IFIT3 and STAT1 gene expression and cell viability in differentiated SH-SY5Y cells. Effects of individual and combined antiretroviral drugs on cell viability and gene expression in differentiated SH-SY5Y cells. (A) Cell viability assessed by MTS assay after 24-hour treatment with tenofovir disoproxil fumarate (TDF, 1.8 μM), dolutegravir (DTG, 20 μM), emtricitabine (FTC, 21 μM), or their combination (cART). (B, C) Relative mRNA expression levels of IFIT3 and STAT1, respectively, in cells treated with lower drug concentrations (TDF at 0.06 μM, DTG at 0.8 μM, FTC at 0.7 μM). (D, E) Relative mRNA expression levels of IFIT3 and STAT1 in cells treated with higher drug concentrations (TDF at 1.8 μM, DTG at 20 μM, FTC at 21 μM). Gene expression was quantified by RT-qPCR, with fold changes calculated relative to untreated control samples. MTS assay results represent the percentage of viable cells compared to control. Independent experiments included n = 9 replicates for RT-qPCR and n = 18 replicates for MTS assay. Statistical significance was determined by one-way ANOVA followed by Dunnett’s multiple comparisons test. *P < 0.0177; **P < 0.0015; ***P < 0.0011; ****P < 0.0001; ns, not significant.

Article Snippet: For primary antibody incubation, the slides were incubated with a mouse anti-IFIT3 primary antibody (Cat no: 15201-1-AP, Proteintech, Rosemont, IL, USA) at a 1:100 dilution and an anti-NeuN antibody, clone A60 (MAB377, MilliporeSigma, Burlington, MA, USA), at 4°C overnight.

Techniques: Gene Expression, MTS Assay, Expressing, Quantitative RT-PCR, Control

Journal: Frontiers in Immunology

Article Title: IFIT3 activation significantly contributes to HIV-1-associated neurodegenerative disorder-mediated neuroinflammation

doi: 10.3389/fimmu.2025.1532318

Figure Lengend Snippet: Effects of Tat and cART on IFIT3 and STAT1 gene expression and cell viability in differentiated SH-SY5Y cells. Effects of HIV-1 Tat protein and cART on SH-SY5Y cell viability, gene expression, and protein levels of IFIT3 and STAT1. (A) Cell viability of differentiated SH-SY5Y cells following treatment with 10, 50, and 100 ng/mL Tat protein for 24 hours, assessed by MTS assay. (B, C) Relative mRNA expression levels of IFIT3 and STAT1 following Tat treatment, evaluated by RT-qPCR. (D, E) IFIT3 and STAT1 gene expression levels after treatment with cART alone or combined Tat+cART treatment. (F, H) Representative Western blot images showing IFIT3 and STAT1 protein levels under different treatment conditions. (G, I) Densitometric analysis of IFIT3 and STAT1 protein expression normalized to β-actin. (J, K) Gene expression analysis of IFIT3 and STAT1 in SH-SY5Y cells treated with HIV, HIV+cART, or cART alone. Fold changes were calculated based on Ct values relative to untreated controls. Western blot quantification was performed using ImageJ, normalizing protein band intensities to β-actin. Independent experiments were performed for RT-qPCR (n = 9), MTS assay (n = 18), and Western blot analysis (n = 3). Statistical significance was determined using one-way ANOVA followed by Dunnett’s multiple comparisons test. *P < 0.05; **P < 0.0082; ***P < 0.001; ****P < 0.0001; ns, not significant.

Article Snippet: For primary antibody incubation, the slides were incubated with a mouse anti-IFIT3 primary antibody (Cat no: 15201-1-AP, Proteintech, Rosemont, IL, USA) at a 1:100 dilution and an anti-NeuN antibody, clone A60 (MAB377, MilliporeSigma, Burlington, MA, USA), at 4°C overnight.

Techniques: Gene Expression, MTS Assay, Expressing, Quantitative RT-PCR, Western Blot

Journal: Frontiers in Immunology

Article Title: IFIT3 activation significantly contributes to HIV-1-associated neurodegenerative disorder-mediated neuroinflammation

doi: 10.3389/fimmu.2025.1532318

Figure Lengend Snippet: Immunocytochemical analysis of IFIT3 and STAT1 protein expression in differentiated SH-SY5Y cells. Immunocytochemical analysis of IFIT3 and STAT1 expression in differentiated SH-SY5Y cells following HIV Tat and cART treatments. (A, D) Representative confocal microscopy images showing IFIT3 and STAT1 protein expression in cells treated with HIV Tat protein, combination cART, or Tat+cART for 24 hours. IFIT3 and STAT1 were detected using Alexa Fluor 488-conjugated antibodies (green), and nuclei were counterstained with DAPI (blue). Phase contrast images detail cellular morphology, and composite images combine all fluorescence channels. (B, E) Quantitative analysis of IFIT3 and STAT1 expression under different treatment conditions. Data were collected from three independent experiments, with 5–6 images per experiment and 5–10 cells analyzed per image. (C, F) Machine learning analysis evaluating classification accuracy based on IFIT3 and STAT1 expression patterns. Statistical significance was assessed using one-way ANOVA followed by Dunnett’s multiple comparisons test. *P < 0.05; **P < 0.0027; ****P < 0.0001; ns, not significant.

Article Snippet: For primary antibody incubation, the slides were incubated with a mouse anti-IFIT3 primary antibody (Cat no: 15201-1-AP, Proteintech, Rosemont, IL, USA) at a 1:100 dilution and an anti-NeuN antibody, clone A60 (MAB377, MilliporeSigma, Burlington, MA, USA), at 4°C overnight.

Techniques: Expressing, Confocal Microscopy, Fluorescence

Journal: Frontiers in Immunology

Article Title: IFIT3 activation significantly contributes to HIV-1-associated neurodegenerative disorder-mediated neuroinflammation

doi: 10.3389/fimmu.2025.1532318

Figure Lengend Snippet: HIV-1 infection increases IFIT3 expression and viral burden in a humanized mouse model. (A) Experimental workflow: Humanized NSG-PBMC mice were engrafted with human PBMCs (Day -2), infected with HIV-1 (Day -1), and initiated on cART (Day 0). Three groups were established: control, HIV-infected, and HIV-infected + cART. Plasma samples were collected on Days 1, 5, and 14 for HIV-1 P24 quantification. On Day 14, brain tissues were harvested for RT-qPCR, Western blot, and immunohistochemistry. (B) Plasma P24 levels confirmed elevated systemic viral load in HIV-infected mice compared to controls. (C) Brain HIV-LTR expression was significantly higher in HIV-infected mice and partially reduced with cART. (D) IFIT3 gene expression was upregulated in brain tissues of HIV-infected mice and attenuated by cART treatment. (E) Western blot analysis showed increased IFIT3 protein expression with HIV infection and partial normalization following cART, with densitometric quantification (F) normalized to β - actin. Statistical significance was determined using one-way ANOVA with Dunnett’s multiple comparisons test for IFIT3 gene and protein expression and a t-test for HIV-LTR results. Significance is indicated as *p = 0.219, ****p < 0.0001, and ns, not significant.

Article Snippet: For primary antibody incubation, the slides were incubated with a mouse anti-IFIT3 primary antibody (Cat no: 15201-1-AP, Proteintech, Rosemont, IL, USA) at a 1:100 dilution and an anti-NeuN antibody, clone A60 (MAB377, MilliporeSigma, Burlington, MA, USA), at 4°C overnight.

Techniques: Infection, Expressing, Control, Clinical Proteomics, Quantitative RT-PCR, Western Blot, Immunohistochemistry, Gene Expression

Journal: Frontiers in Immunology

Article Title: IFIT3 activation significantly contributes to HIV-1-associated neurodegenerative disorder-mediated neuroinflammation

doi: 10.3389/fimmu.2025.1532318

Figure Lengend Snippet: (A) Immunohistochemical analysis of cerebellum brain tissue from humanized mice subjected to HIV-1 and cART is shown in the remaining panels. Representative images illustrate IFIT3 expression (green fluorescence), neuronal cells labeled with the NeuN marker (red fluorescence), and nuclear staining with DAPI (blue fluorescence). Column 1 shows IFIT3 expression. Column 2, NeuN labeling; Column 3, DAPI staining; Column 4, a composite image of IFIT3, NeuN, and DAPI. Column 5 shows phase contrast (PC) imaging to detail the cellular morphology. Column 6 shows a composite overlay of IFIT3/NeuN/DAPI with phase contrast imaging to provide a holistic view of expression patterns within the cellular architecture. (B) shows the fluorescence intensity, and (C) shows the accuracy analysis via MATLAB. The study included brain tissue samples from six individual mice (n=6) in each treatment group.Differences in IFIT3 expression were statistically analyzed via one-way ANOVA with Dunnett’s multiple comparisons test. Significance levels are indicated as *p = 0.219, ****p < 0.0001 and ns, not significant.

Article Snippet: For primary antibody incubation, the slides were incubated with a mouse anti-IFIT3 primary antibody (Cat no: 15201-1-AP, Proteintech, Rosemont, IL, USA) at a 1:100 dilution and an anti-NeuN antibody, clone A60 (MAB377, MilliporeSigma, Burlington, MA, USA), at 4°C overnight.

Techniques: Immunohistochemical staining, Expressing, Fluorescence, Labeling, Marker, Staining, Imaging

Journal: JCI Insight

Article Title: Alternative exon usage in TRIM21 determines the antigenicity of Ro52/TRIM21 in systemic lupus erythematosus

doi: 10.1172/jci.insight.163795

Figure Lengend Snippet: ( A ) Neutrophils (PMN) and PBMCs from 19 consecutive patients with SLE were analyzed by immunoblotting using antibodies to IFIT3, histone H3 (H3), and β-actin (loading controls). Representative samples from 9 patients are shown. ( B – H ) Lysates from SLE neutrophils and PBMCs with low and high activation by IFN based on IFIT3 expression ( B ) were used to screen 20 SLE sera ( C ) and 5 commercial antibodies to Ro52 ( D – H ). H3 is shown as loading control in B . In C , data from 5 SLE sera recognizing a set of autoantigens overexpressed in SLE neutrophils with high IFIT3 expression are shown.

Article Snippet: Mouse monoclonal anti–human IFIT3 (H00003437-B01) was purchased from Abnova, mouse monoclonal anti–human Ro52 (clone D-12) was purchased from Santa Cruz Biotechnology Inc., rabbit anti–N-terminal TRIM21 polyclonal antibody was purchased from Origene (TA335782), rabbit anti–human TRIM21 polyclonal antibody was purchased from Proteintech (121081-1-AP), mouse anti–human TRIM21 monoclonal antibody was purchased from Proteintech (671361-1-Ig), rabbit anti–C-terminal TRIM21 polyclonal antibody was purchased from MilliporeSigma (AV381248), mouse anti–human β-actin was purchased from MilliporeSigma (A5316), and mouse anti–human histone H3 was purchased from Cell Signaling Technology (96C10).

Techniques: Western Blot, Activation Assay, Expressing, Control

Journal: JCI Insight

Article Title: Alternative exon usage in TRIM21 determines the antigenicity of Ro52/TRIM21 in systemic lupus erythematosus

doi: 10.1172/jci.insight.163795

Figure Lengend Snippet: ( A and B ) Neutrophils (PMN) and PBMCs from 19 consecutive patients with SLE were analyzed by immunoblotting using antibodies to IFIT3, Ro52 (D-12 mouse monoclonal antibody), histone H3 (H3), and β-actin (loading controls). Representative data from 10 patients are shown. ( C and D ) Correlation between the expression of IFIT3 and Ro52 in PMN and PBMCs. The expression of Ro52 and IFIT3 was quantified by densitometry from the corresponding bands in A and B , and the values were fitted to a linear regression model. ( E ) PBMCs and PMN from 12 healthy controls (Ctrl) and 1 patient with SLE were analyzed by immunoblotting using antibodies to IFIT3, Ro52 (D-12 mouse monoclonal antibody), and H3 (loading control). Representative data from 6 healthy controls are shown. The SLE samples were included for comparison.

Article Snippet: Mouse monoclonal anti–human IFIT3 (H00003437-B01) was purchased from Abnova, mouse monoclonal anti–human Ro52 (clone D-12) was purchased from Santa Cruz Biotechnology Inc., rabbit anti–N-terminal TRIM21 polyclonal antibody was purchased from Origene (TA335782), rabbit anti–human TRIM21 polyclonal antibody was purchased from Proteintech (121081-1-AP), mouse anti–human TRIM21 monoclonal antibody was purchased from Proteintech (671361-1-Ig), rabbit anti–C-terminal TRIM21 polyclonal antibody was purchased from MilliporeSigma (AV381248), mouse anti–human β-actin was purchased from MilliporeSigma (A5316), and mouse anti–human histone H3 was purchased from Cell Signaling Technology (96C10).

Techniques: Western Blot, Expressing, Control, Comparison

Journal: Journal of Virology

Article Title: Dysregulation of Cellular VRK1, BAF, and Innate Immune Signaling by the Vaccinia Virus B12 Pseudokinase

doi: 10.1128/jvi.00398-22

Figure Lengend Snippet: Antibody sources and dilutions

Article Snippet: Mouse monoclonal anti-IFIT3 , Santa Cruz Biotechnology , B-7 , 1:500 , sc-393512.

Techniques: